L-CCG-l

Pricing Availability   Qty
Description: Potent group II mGlu agonist
Alternative Names: (2S,3S,4S)-CCG
Chemical Name: (2S,1'S,2'S)-2-(Carboxycyclopropyl)glycine
Purity: ≥99% (HPLC)
Datasheet
Citations (4)
Reviews
Literature (4)

Biological Activity for L-CCG-l

L-CCG-l is a potent group II metabotropic glutamate receptor agonist. More active than glutamate or (±)-trans-ACPD (Cat. No. 0187).

Technical Data for L-CCG-l

M. Wt 159.14
Formula C6H9NO4
Storage Store at RT
Purity ≥99% (HPLC)
CAS Number 117857-93-9
PubChem ID 5310956
InChI Key GZOVEPYOCJWRFC-HZLVTQRSSA-N
Smiles N[C@]([H])(C(O)=O)[C@@]([H])(C1)[C@]1([C@@](O)=O)[H]

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for L-CCG-l

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
1eq. NaOH 100

Preparing Stock Solutions for L-CCG-l

The following data is based on the product molecular weight 159.14. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 6.28 mL 31.42 mL 62.84 mL
5 mM 1.26 mL 6.28 mL 12.57 mL
10 mM 0.63 mL 3.14 mL 6.28 mL
50 mM 0.13 mL 0.63 mL 1.26 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

Product Datasheets for L-CCG-l

Certificate of Analysis / Product Datasheet
Select another batch:

References for L-CCG-l

References are publications that support the biological activity of the product.

Brabet et al (1998) Comparative effect of L-CCG-I, DCG-IV and γ-carboxy-L-glutamate on all cloned metabotropic glutamate receptor subtypes. Neuropharmacology 37 1043 PMID: 9833633

Hayashi et al (1992) Agonist analysis of 2-(carboxycyclopropyl)glycine isomers for cloned metabotropic glutamate receptor subtypes expressed in Chinese hamster ovary cells. Br.J.Pharmacol. 107 539 PMID: 1330184

Shinozaki et al (1989) Potent NMDA-like actions and potentiation of glutamate responses by conformational variants of a glutamate analogue in the rat spinal cord. Br.J.Pharmacol. 98 1213 PMID: 2692753

Wright and Schoepp (1996) Differentiation of group 2 and group 3 metabotropic glutamate receptor cAMP responses in the rat hippocampus. Eur.J.Pharmacol. 297 275 PMID: 8666060


If you know of a relevant reference for L-CCG-l, please let us know.

View Related Products by Product Action

View all Glutamate (Metabotropic) Group II Receptor Agonists

Keywords: L-CCG-l, L-CCG-l supplier, Potent, group, II, mGlur, agonists, Group, Receptors, mGlu2, mGlu3, mGluR2, mGluR3, Glutamate, Metabotropic, (2S,3S,4S)-CCG, (Metabotropic), 0333, Tocris Bioscience

4 Citations for L-CCG-l

Citations are publications that use Tocris products. Selected citations for L-CCG-l include:

Scholler (2017) HTS-compatible FRET-based conformational sensors clarify membrane receptor activation. Nat Chem Biol 13 372 PMID: 28135236

Caiati et al (2012) Developmental regulation of CB1-mediated spike-time dependent depression at immature mossy fiber-CA3 synapses. Sci Rep 2 285 PMID: 22368777

Ster et al (2011) Enhancement of CA3 hippocampal network activity by activation of group II metabotropic glutamate receptors. Neuron 108 9993 PMID: 21628565

Han et al (2015) Alleviation of kainic acid-induced brain barrier dysfunction by 4-o-methylhonokiol in in vitro and in vivo models. Biomed Res Int 2015 893163 PMID: 25688368


Do you know of a great paper that uses L-CCG-l from Tocris? Please let us know.

Reviews for L-CCG-l

There are currently no reviews for this product. Be the first to review L-CCG-l and earn rewards!

Have you used L-CCG-l?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Metabotropic Glutamate Receptors Scientific Review

Metabotropic Glutamate Receptors Scientific Review

Written by Francine Acher, this review discusses the pharmacology and therapeutic potential of mGlu receptors, and the compounds acting upon them; compounds available from Tocris are listed.

Addiction Poster

Addiction Poster

The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.